ReviewJournal of diabetes science and technology2018
Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue.
Review in Journal of diabetes science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.Acta diabetologica · 2020Pooled it
- A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.Diabetes technology & therapeutics · 2022Trial
- Integrated Experimental and Molecular Modeling Techniques to Investigate the Buffer Effects on Glucagon Stability.Pharmaceutical research · 2026Article
- Article
- Review
- Secondary Structure Characterization of Glucagon Products by Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy.Molecules (Basel, Switzerland) · 2022Article
- Review
- A metamodel-based flexible insulin therapy for type 1 diabetes patients subjected to aerobic physical activity.Scientific reports · 2022Article
- Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.Artificial organs · 2021Review
- Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?Biomolecules · 2021Review
- Glucagon Therapy: A Comparison of Current and Novel Treatments.Diabetes spectrum : a publication of the American Diabetes Association · 2020Article
- Where Do We Stand with Closed-Loop Systems and Their Challenges?Diabetes technology & therapeutics · 2020Review
- Role of Glucagon in Automated Insulin Delivery.Endocrinology and metabolism clinics of North America · 2020Review
- Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.Current diabetes reports · 2019Review
- Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.Journal of diabetes science and technology · 2019Article
- Advances in Type 1 Diabetes Technology Over the Last Decade.European endocrinology · 2019Review
- Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review.Diabetes spectrum : a publication of the American Diabetes Association · 2019Article
- Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia.International journal of molecular sciences · 2019Review
- New uses and formulations of glucagon for hypoglycaemia.Drugs in context · 2019Review
- Could Age, Sex and Physical Fitness Affect Blood Glucose Responses to Exercise in Type 1 Diabetes?Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post-bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.